Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Market Cap: US$1.0b

Viridian Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Steve Mahoney

Chief executive officer

US$13.0m

Total compensation

CEO salary percentage0.9%
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure3.8yrs

Recent management updates

Recent updates

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Jun 12

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

May 28
Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12
Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15
Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22
An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Viridian Therapeutics gets a new COO

Jun 23

Viridian Therapeutics (VRDN) Investor Presentation - Slideshow

Jun 08

CEO Compensation Analysis

How has Steve Mahoney's remuneration changed compared to Viridian Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$218m

Dec 31 2023US$13mUS$113k

-US$238m

Compensation vs Market: Steve's total compensation ($USD13.02M) is above average for companies of similar size in the US market ($USD3.22M).

Compensation vs Earnings: Insufficient data to compare Steve's compensation with company performance.


CEO

Steve Mahoney (53 yo)

less than a year

Tenure

US$13,022,654

Compensation

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Mahoney
CEO, President & Directorless than a yearUS$13.02mno data
Seth Harmon
Senior VP of Finance and Accountingless than a yearUS$6.67m0.0016%
$ 15.9k
Thomas Beetham
Chief Operating Officerless than a yearUS$5.17mno data
Eric Olson
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Michael Bristow
Co-Founder & Member of the Scientific Advisory Boardno datano datano data
Marvin Caruthers
Co-Founder & Scientific Advisory Board Memberno datano datano data
Vahe Bedian
Co-Founder & Scientific Advisorno datano datano data
Jennifer Tousignant
Chief Legal Officerless than a yearno datano data
John Jordan
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Anthony Casciano
Chief Commercial Officer1.3yrsno datano data
Thomas Ciulla
Chief Medical Officer1.5yrsno data0.0012%
$ 12.0k
Shan Wu
Chief Business Officerless than a yearno datano data

0.8yrs

Average Tenure

53.5yo

Average Age

Experienced Management: VRDN's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Stephen Mahoney
CEO, President & Directorless than a yearUS$13.02mno data
Eric Olson
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Michael Bristow
Co-Founder & Member of the Scientific Advisory Boardno datano datano data
Marvin Caruthers
Co-Founder & Scientific Advisory Board Memberno datano datano data
Arlene Morris
Independent Director6.5yrsUS$477.83k0%
$ 0
Victor Ambros
Scientific Advisory Board Memberno datano datano data
Stefanie Dimmeler
Scientific Advisory Board Memberno datano datano data
Jeffery Molkentin
Scientific Advisory Board Memberno datano datano data
Eva van Rooij
Scientific Advisory Board Memberno datano datano data
Tomas Kiselak
Independent Chairperson of Board3.8yrsUS$503.83k0%
$ 0
Jennifer Moses
Independent Director3yrsUS$467.83k0%
$ 0
Peter Harwin
Independent Director3.8yrsUS$471.83k0%
$ 0

3.8yrs

Average Tenure

53yo

Average Age

Experienced Board: VRDN's board of directors are considered experienced (3.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.